- Home
- EEA vs APLT Comparison
EEA vs APLT Comparison
Compare EEA & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EEA
- APLT
- Stock Information
- Founded
- EEA 1986
- APLT 2016
- Country
- EEA Germany
- APLT United States
- Employees
- EEA N/A
- APLT N/A
- Industry
- EEA Trusts Except Educational Religious and Charitable
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- EEA Finance
- APLT Health Care
- Exchange
- EEA Nasdaq
- APLT Nasdaq
- Market Cap
- EEA 67.9M
- APLT 69.0M
- IPO Year
- EEA N/A
- APLT 2019
- Fundamental
- Price
- EEA $10.66
- APLT $0.44
- Analyst Decision
- EEA
- APLT Buy
- Analyst Count
- EEA 0
- APLT 6
- Target Price
- EEA N/A
- APLT $6.10
- AVG Volume (30 Days)
- EEA 9.2K
- APLT 896.6K
- Earning Date
- EEA 01-01-0001
- APLT 11-06-2025
- Dividend Yield
- EEA 1.92%
- APLT N/A
- EPS Growth
- EEA N/A
- APLT N/A
- EPS
- EEA N/A
- APLT N/A
- Revenue
- EEA N/A
- APLT $121,000.00
- Revenue This Year
- EEA N/A
- APLT N/A
- Revenue Next Year
- EEA N/A
- APLT $5,931.24
- P/E Ratio
- EEA N/A
- APLT N/A
- Revenue Growth
- EEA N/A
- APLT N/A
- 52 Week Low
- EEA $7.45
- APLT $0.30
- 52 Week High
- EEA $9.26
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- EEA 58.73
- APLT 42.40
- Support Level
- EEA $10.42
- APLT $0.46
- Resistance Level
- EEA $10.83
- APLT $0.53
- Average True Range (ATR)
- EEA 0.19
- APLT 0.03
- MACD
- EEA -0.01
- APLT -0.01
- Stochastic Oscillator
- EEA 60.33
- APLT 0.00
About EEA The European Equity Fund Inc.
European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.